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Abstract
Background: Our objective was to find single nucleotide polymorphisms (SNPs), within transcriptional pathways of
glucose and lipid metabolism, which are related to multiple features of the metabolic syndrome (MetS).
Methods: 373 SNPs were measured in 3575 subjects of the Doetinchem cohort. Prevalence of MetS features, i.e.
hyperglycemia, abdominal obesity, decreased HDL-cholesterol levels and hypertension, were measured twice in 6
years. Associations between the SNPs and the individual MetS features were analyzed by log-linear models. For
SNPs related to multiple MetS features (P < 0.01), we investigated whether these associations were independent of
each other.
Results: Two SNPs, CETP Ile405Val and APOE Cys112Arg, were associated with both the prevalence of low HDL-
cholesterol level (Ile405Val P = < .0001; Cys112Arg P = 0.001) and with the prevalence of abdominal obesity
(Ile405Val P = 0.007; Cys112Arg P = 0.007). For both SNPs, the association with HDL-cholesterol was partly
independent of the association with abdominal obesity and vice versa.
Conclusion: Two SNPs, mainly known for their role in lipid metabolism, were associated with two MetS features i.e.,
low HDL-cholesterol concentration, as well as, independent of this association, abdominal obesity. These SNPs may
help to explain why low HDL-cholesterol levels and abdominal obesity frequently co-occur.
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Introduction
The metabolic syndrome (MetS) is a common multi-
component condition including abdominal obesity, dysli-
pidemia, hypertension, and hyperglycemia. It is asso-
ciated with an increased risk of cardiovascular disease
and type 2 diabetes [1]. A central question in under-
standing the MetS is why these traits cluster together
[1]. The clustering may be explained by a complex phy-
siological cascade of events, in which the occurrence of
one trait initiates the occurrence of a second. Alterna-
tively, a causative factor common to several metabolic
traits may explain the clustering. This factor could be
either of genetic or environmental nature [2].
Family and twin studies indicate that the different fea-
tures of the MetS share a common genetic component
[2-5]. Twin studies show that the correlation between the
features of the metabolic syndrome is higher in monozy-
gotic compared to dizygotic twins [2,6,7]. Family studies
also show significant genetic correlations between the dif-
ferent features of the metabolic syndrome [4]. Heritability
estimates of the MetS itself range from 13-27% [3-5].
However, despite the evidence from these heritability stu-
dies, only a few single nucleotide polymorphisms (SNPs)
have been linked to multiple features of the MetS[1].
Disturbances in lipid and glucose metabolism may lead
to the development of one or more MetS features [8].
Therefore, genes involved in these pathways are poten-
tially pleiotropic for multiple MetS features. In a popula-
tion based cohort study, we studied 373 SNPs mainly
selected from transcriptional pathways of glucose and
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lipid metabolism, and their association with multiple fea-
tures of the MetS.
Methods
Study population
The Doetinchem Study is a population-based cohort
study on lifestyle, biological risk factors and chronic dis-
eases [9]. Between 1987 and 1991, 12404 subjects, aged
20-59, all inhabitants of Doetinchem, a town in a rural
area in east of the Netherlands, were enrolled in the base-
line cohort. A random sub-sample of this cohort (63%)
was invited for a second measurement round (1993-1997;
response 79%) and for a third measurement round (1998-
2002; response 75%). Overall, the Doetinchem Cohort
comprises 4662 persons with repeated measurements.
Pregnancy and alteration in smoking behavior are fac-
tors that influence body weight and therewith the MetS.
Therefore, subjects of the Doetinchem Cohort who chan-
ged their smoking habits (n = 750), who had missing data
on smoking status (n = 11) or who where pregnant at the
time of measurement (n = 122) were excluded from the
current study. This resulted in a final study population of
3779 subjects. The second and third measurement rounds
included glucose and waist circumference measurements
and were used for the present study. All participants gave
written informed consent and approval was obtained from
local Medical-Ethical Committees.
Measurements
During each measurement round, a questionnaire on
lifestyle factors was administered and anthropometric
and biochemical variables were measured. For a more
detailed description see [10].
During the second and third visit waist circumference
was measured according to written instructions based on
WHO criteria for waist measurement (1989). Waist cir-
cumference was determined to the nearest 0.5 cm, at mid-
way between the lowest rib and the iliac crest, with
subjects in standing position and after breathing out gently.
Waist circumference was measured in duplicate and the
mean of the two measurements was taken. Blood pressure
(BP) was measured in each round, with the subject in sit-
ting position using a random-zero sphygmomanometer.
Systolic pressure was recorded at the appearance of sounds
(first-phase Korotkoff) and diastolic blood pressure was
recorded at the disappearance of sounds (fifth-phase
Korotkoff). BP measurement was repeated and values were
averaged. During the physical examination, regular audits
were performed to check adherence to the BP measuring
protocol (e.g. resting time, adequate cuff size).
Non-fasting blood samples were taken by venapuncture
for all subjects. Blood samples were fractionated into
serum, buffy coat and erythrocytes and subsequently
stored at -30°C until further use. Plasma glucose levels
were measured as described by Tietz [11]. HDL-choles-
terol was measured in EDTA-plasma until 1998, and
from 1998 onwards in serum, at the Lipid Reference
Laboratory (LRL) of the university Hospital Dijkzigt in
Rotterdam, using standardized enzymatic methods. Per-
formance for enzymatic HDL-cholesterol measurements
fulfilled National Cholesterol Education Program (NCEP)
recommendations throughout the entire study period.
Genomic DNA was extracted from the buffy coat frac-
tion with a salting out method. A total of 139 subjects
were not eligible for genotyping, mainly because of fail-
ure to extract DNA or unavailability of buffy coats. For
3640 subjects, 401 SNP across 270 candidate genes were
genotyped. A set of 383 SNP’s across 253 candidate
genes, passed the Illumina design tool and were geno-
typed with the Illumina Golden Gate assay using the
Sentrix Array Matrix platform (Illumina Inc, San Diego,
California) [11]. 18 Additional SNPs were genotyped by
KBioscience (Hoddesdon, Hertfordshire, UK) using the
KASPar chemistry, which is a competitive allele specific
PCR SNP genotyping system using FRET quencher cas-
sette oligonucleotides http://www.kbioscience.co.uk).
Two SNPs (rs7412 and rs429358 in APOE) that failed in
the Illumina Golden Gate assay were successfully re-
genotyped with Taqman assay.
A detailed description of the SNP selection procedure
and a full SNP list have been published elsewhere [10]. In
short, 270 candidate genes were selected by a pathway-
driven approach, with emphasis on regulatory pathways
that control fatty acid, glucose, cholesterol and bile
salt homeostasis [10]. The selection procedure started
from the master regulator genes encoding nuclear recep-
tors (PPARs, LXR, NR1H4) and transcription factors
(SREBPs) and continued by selecting their co-activators,
co-repressors and target genes. In addition, hormonal
receptors (insulin receptor), their down-stream signaling
proteins and genes involved in b-signaling were selected.
For each gene out of these pathways, 1-7 SNPs most
likely to carry functional properties were selected. For 26
SNPs genotyping was unsuccessful. In addition, 33 SNPs
were not in Hardy Weinberg Equilibrium (HWE). Verifi-
cation was carried out in a random sample (n = 96) for
the eight SNPs (24%) that deviated most strongly from
HWE. All yielded the same results, except for 2 SNPs,
which were therefore excluded [10]. After the exclusion
of subjects with genotype failure or discordance on gen-
der control (n = 65), 3575 subjects were available for data
analyses. Finally, data on 373 SNPs in 254 genes were
available for 3575 subjects.
Statistical analyses
Abdominal obesity, low HDL-cholesterol levels, hyper-
glycemia and hypertension were defined according to
the criteria of the AHA/NHLBI (2005)[12].
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All analyses were performed with SAS version 9.1
(SAS Institute, INC., Cary, North Carolina). Distribu-
tions of genotypes were tested for deviation from HWE
by chi-square analyses (PROC ALLELE). Associations
with individual MetS features and co-occurrence of
MetS features were tested. To optimize precision, sub-
jects who changed phenotype between the two rounds
were excluded. This means that subjects being e.g.
hypertensive in one round and normotensive in the
other round or vice versa were excluded. All analyses
were adjusted for age and sex.
In a first series of analyses, the association between
individual MetS features and each SNP was analyzed by
log-linear models. The prevalence ratios of change per
allele were calculated with an additive genetic model.
To avoid chance findings we only followed up those
SNPs which were related to multiple MetS features with
P ≤ 0.01. We determined the expected number of SNPs
related to 2 or more MetS features with P < 0.01 by
chance alone and under the assumption of independent
random outcomes using the following formula: Chance
(P ≤ 0.01 for SNP_1 - MetS feature_1 association) *
Chance (P ≤ 0.01 for the SNP_2 - MetS feature_2 asso-
ciation) * Chance (association 1 and 2 in the same direc-
tion) * number of MetS feature combinations * number
of SNPs. The expected number appeared to be 0.12
(0.01 * 0.01 * 0.5 * 6 * 373). Subsequently we tested
whether the number of observed SNPs associated with 2
or more MetS features differed significantly from the
expected 0.12 SNPs.
In our study abdominal obesity and decreased HDL-
cholesterol appeared to be the MetS features both asso-
ciated with the same SNPs. In a second series of ana-
lyses, it was tested if the association between these SNPs
and HDL-cholesterol was independent of the association
with abdominal obesity, and vice versa. This was done
both by adjustment and by stratification. The HDL-cho-
lesterol analyses were adjusted for abdominal obesity
and vice versa. For stratified analyses, the association
with abdominal obesity was analyzed in subjects with
high HDL-cholesterol levels. Low HDL-cholesterol was
analyzed in subjects without abdominal obesity.
Results
Baseline characteristics among the 3575 subjects of the
Doetinchem cohort are presented in table 1. Hyperten-
sion was the most prevalent MetS feature (41.6% of the
subjects were stable hypertensive and 32.3% of the sub-
jects were stable normotensive). The least prevalent
MetS feature was low HDL-cholesterol (18.7% were
stable for low HDL and 64.1% were stable for high
HDL). The most frequent combination of co-occurring
MetS features was hypertension and abdominal obesity
(14.5% were stable positive, 21.2% were stable negative).
The least frequent combination was decreased HDL-
cholesterol levels and hyperglycemia (3.5% were stable
positive, 32.6% were stable negative).
19 SNPs were related to at least one of the stable MetS
features with P < 0.01 (table 2). Two of them, Ile405Val
(rs5882) in the Cholesteryl Ester Transfer Protein (CETP)
gene and Cys112Arg (rs429358) in the Apolipoprotein E
(APOE) gene were related to 2 MetS features each with P
< 0.01. This number differs significantly from the
expected 0.12 SNPs to be associated with two features or
more by chance alone (p < 0.005 chi-square with Yates
correction). Both SNPs were in HWE (Ile405Val P =
0.21; Cys112Arg P = 0.48). The minor Val allele of Ile405-
Val in the CETP gene was associated with both a
decreased prevalence of low HDL-cholesterol levels (PR/
allele 0.76, 95%CI 0.69; 0.86) and a decreased prevalence
of abdominal obesity (PR/allele 0.90, 95%CI 0.83; 0.97)
(table 3). The minor Arg allele of the Cys112Arg in the
APOE gene was associated with an increased prevalence
of low HDL-cholesterol levels (PR/allele 1.21, 95% CI
1.07; 1.37) and an increased prevalence of abdominal
obesity (PR/allele 1.12, 95% CI 1.03; 1.23) (table 4).
Results for both SNPs remained significant after adjust-
ing the abdominal obesity analyses for HDL-cholesterol
and vice versa. Further analyses showed that both SNPs
were associated with the simultaneous occurrence of
abdominal obesity and low HDL-cholesterol levels, with
decreased HDL-cholesterol levels in a subgroup of people
without abdominal obesity, and with abdominal obesity
in a subgroup of people with normal HDL-cholesterol
levels (table 3; table 4).
The Cys112Arg genotype of the APOE gene is part of
the ε2, ε3, ε4 haplotype. Results of the ε2ε3ε4 haplotype
analyses were similar to the results of the Cys112Arg
analyses. Compared to the ε3/ε3 isoform, the ε4/- iso-
forms (ε3/ε4 and ε4/ε4) were associated with an
increased prevalence of low HDL-cholesterol levels (PR
1.24, 95%CI 1.07; 1.44) and an increased prevalence of
abdominal obesity (PR 1.13, 95%CI 1.01; 1.26). No asso-
ciations were found with the ε2/- isoforms (ε3/ε2 and
ε2/ε2).
Discussion
In this explorative study of 373 SNPs, mainly located in
pathways related to lipid and glucose metabolism, we
found a significant association between the Ile405Val
genotype in the CETP gene and the Cys112Arg genotype
in the APOE gene, with multiple features of the meta-
bolic syndrome, i.e. the prevalence of abdominal obesity
and prevalence of low HDL-cholesterol. For both SNPs,
the association with abdominal obesity was partly inde-
pendent of the association with HDL-cholesterol, and
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vice versa. No, association was found between SNPs in
genes involved in glucose metabolism or blood pressure
regulation and multiple MetS features.
In humans, CETP and ApoE are expressed in the liver
and in peripheral tissues, such as adipose tissue [13,14].
Both genes are involved in plasma lipid homeostasis.
CETP stimulates the clearance of HDL-cholesterol from
plasma [14]. Furthermore, CETP increases the formation
of small dense LDL particles and triglycerides [15].
ApoE removes atherogenic lipoproteins, such as VLDL,
from the circulation [16]. This results in lower choles-
terol and triglyceride levels. Besides having a role in
lipid homeostasis, a few studies indicate that CETP and
ApoE may be involved in other metabolic processes
such as weight regulation. For example, APOE plays a
role in the deposition of dietary fat in adipose tissue
[17]. As CETP is synthesized in the adipose tissue,
CETP may affect adipose tissue characteristics [18].
The Ile405Val polymorphism in the CETP gene
induces a change in amino acid sequence. Therefore it
is likely to be a functional SNP. In our study, the Val
allele of the Ile405Val genotype was associated with a
lower prevalence of abdominal obesity and a lower pre-
valence of low HDL-cholesterol levels. The stratified
and adjusted analyses in our study suggested that the
association with prevalence of abdominal obesity and
prevalence of low HDL-cholesterol levels was partly
independent of each other. This suggests that CETP reg-
ulates weight and HDL-cholesterol via independent
pathways.
Table 1 Characteristics of 3575 subjects of the Doetinchem Cohort in round 2 and 3
Round 2: 1993-1997 Round 3: 1998-2002
Age (yr) 46.5 (9.7) 51.5 (9.7)
Sex (% men) 47.8 47.8
Waist circumference (cm) 90.2 (11.1) 92.9 (11.4)
Increased waist circumference (%)a 31.3 40.3
Glucose levels (mmol/L)b 5.3 (1.3) 5.4 (1.5)
Diabetic medication (%) 0.8 2.3
Hyperglycemia (%)a 28.8 33.6
HDL-cholesterol (mmol/L) 1.38 (0.38) 1.37 (0.39)
Low HDL-cholesterol (%)a 25.4 29.0
Diastolic Blood Pressure (mm Hg) 79.9 (10.6) 81.4 (10.7)
Systolic Blood Pressure (mm Hg) 125.1 (16.4) 129.3 (18.01)
Hypertension (%)a 50.8 58.5
Blood Pressure lowering medication (%) 6.5 11.0
MetS-score (number of features) 1.34 (1.1) 1.61 (1.1)
Metabolic syndrome prevalence (%) 14.9 22.7
Data are presented as means (standard deviation) or %
aAbdominal obesity, hyperglycemia, low HDL, hypertension and MetS are defined according to the criteria of AHA-NHLBI (2005). Abdominal obesity: ♂ ≥ 102 cm;
♀ ≥ 88 cm; Low HDL: ♂ < 1.0; ♀ < 1.3 mmol/L; hypertension: ≥ 130/85 mm Hg or hypertensive medicine; Hyperglycemia ≥ 5.6 (mmol/L) or glucose lowering
medication; MetS is defined as having 3 MetS features measured in Doetinchem Cohort
bNon-fasting values
Table 2 SNP’s associated (P < 0.01) with stable MetS
features among subjects of the Doetinchem Cohort over
2 surveys (1993-1997; 1998-2002)
SNP MAF Gene PR/allele (95%CI) P-Value
Hyperglycemia (n = 2280)
rs1137101 0.46 LEPR 0.84 (0.76; 0.93) 0.001
rs3842748 0.21 INS-IGF2 1.20 (1.07; 1.35) 0.002
rs6795441 0.45 RAF1 0.86 (0.77; 0.95) 0.003
rs7903146 0.29 TCF7L2 1.17 (1.05; 1.30) 0.005
rs1143634 0.24 IL1B 1.17 (1.05; 1.31) 0.005
Abdominal obesity (n = 2931)
rs35724 0.38 NR1H4 0.91 (0.85; 0.97) 0.005
rs10860603 0.14 NR1H4 0.86 (0.78; 0.96) 0.006
rs1800796 0.04 IL6 0.77 (0.64;0.93) 0.007
rs5882 0.31 CETP 0.90 (0.83;0.97) 0.007
rs429358 0.16 APOE 1.12 (1.03;1.23) 0.007
Hypertension (n = 2643)
rs130005 0.10 CREBBP 0.89 (0.82; 0.97) 0.006
rs3759324 0.25 SCCN1A 1.07 (1.02; 1.12) 0.009
Low HDL-Cholesterol (n = 2959)
rs1800777 0.03 CETP 1.60 (1.56;2.32) 3.3 E-12
rs3208305 0.30 LPL 0.70 (0.63;0.79) 9.3 E-10
rs328 0.11 LPL 0.60 (0.49; 0.72) 1.2 E-7
rs5882 0.31 CETP 0.76 (0.69;0.86) 2.1 E-6
rs429358 0.16 APOE 1.21 (1.07;1.37) 0.001
rs174546 0.33 FADS1 1.18 (1.07;1.30) 0.001
rs780094 0.36 GCKR 1.17 (1.06; 1.29) 0.002
rs268 0.02 LPL 1.45 (1.12; 1.86) 0.004
rs5275 0.31 PTGS2 1.15 (1.04; 1.27) 0.006
MAF = Minor allele frequency; PR = Prevalence Ratio; b Prevalence ratios are
expressed per minor allele assuming an additive genetic model
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In line with our results, a meta-analysis of 29 studies,
showed that Val allele carriers had higher HDL levels
[19]. Furthermore, a Chinese case-control study in 934
obesity cases and 924 controls showed a decreased obe-
sity risk for Val/Val homozygotes, which persisted after
adjustment for HDL-cholesterol levels [20]. In previous
studies, the 405Val allele has been associated with lower
CETP mass and lower CETP activity [19]. Lower CETP
plasma levels are correlated with a lower obesity risk
[21]. The 405Val allele has also been associated with
Table 3 Association of Ile405Val (rs5882) in the CETP gene with abdominal obesity and low HDL-cholesterol levels
Outcomea Ile/Ile Ile/Val Val/Val PR/allele (95%CI)b P-trend
Prevalence of low HDLc
Overall
(n = 669, total n = 2959)
26.0% 20.6% 14.4% 0.76 (0.69;0.86) < .0001
Adjusted for abdominal obesity
(n = 669, total n = 2959)
24.7% 21.3% 16.0% 0.83 (0.74;0.93) 0.002
Among subjects without abdominal obesity
(n = 252, total n = 1684)
18.4% 13.0% 7.8% 0.68 (0.56;0.82) < 0.001
Prevalence of abdominal obesityd
Overall
(n = 958, total n = 2931)
34.7% 31.9% 26.4% 0.90 (0.83;0.97) 0.0072
Adjusted for low HDL
(n = 958, total n = 2931)
33.1% 30.4% 27.0% 0.92 (0.83;1) 0.05
Among subjects with high HDL levels
(n = 470, total n = 1902)
27.9% 22.8% 18.7% 0.82 (0.73;0.93) 0.0014
Prevalence of both low HDL and abdominal obesitye
Overall
(n = 298, total n = 1730)
19.5% 16.3% 11.2% 0.81 (0.69;0.94) 0.0076
PR = Prevalence Ratio
a All analyses are adjusted for age and sex
b Prevalence ratios are expressed per minor VAL allele assuming an additive genetic model
c Subjects with low HDL-cholesterol in round 2, but not in round 3 or vice versa, were excluded
d Subjects with abdominal obesity in round 2, but not round 3 or vice versa, were excluded
e Only subjects with either both abdominal obesity and low HDL-cholesterol levels in round 2 and 3 or with both no abdominal obesity and high HDL-
cholesterol levels were included. Subjects without abdominal obesity and with high HDL-cholesterol levels in round 2 and 3 were used as the reference category
Table 4 Association of Cys112Arg (rs429358) in the APOE gene with abdominal obesity and low HDL-cholesterol levels
Outcomea Cys/Cys Cys/Arg Arg/Arg PR/allele (95%CI) b P-trend
Prevalence of low HDLc
Overall
(n = 669, total n = 2959)
21.2% 25.5% 32.3% 1.21 (1.07;1.37) 0.0013
Adjusted for abdominal obesity
(n = 669, total n = 2959)
21.0% 25.5% 30.2% 1.20 (1.06;1.36) 0.005
Among subjects without abdominal obesity
(n = 252, total n = 1684)
13.5% 18.0% 26.0% 1.35 (1.11; 1.65) 0.0031
Prevalence of abdominal obesityd
Overall
(n = 958, total n = 2931)
31.2% 35.8% 39.6% 1.12 (1.03;1.23) 0.0074
Adjusted for low HDL
(n = 958, total n = 2931)
30.1% 33.1% 38.9% 1.12 (1.0l;1.25) 0.04
Among subjects with high HDL levels
(n = 470, total n = 1902)
23.5% 27.3% 34.5% 1.16 (1.01;1.33) 0.03
Prevalence of both low HDL and abdominal obesitye
Overall
(n = 298, total n = 1730)
15.7% 20.7% 27.8% 1.29 (1.08;1.54) 0.0045
PR = Prevalence Ratio
aAll analyses are adjusted for age and sex
b Prevalence ratios are expressed per minor ARG allele assuming an additive genetic model
c Subjects with low HDL-cholesterol in round 2, but not in round 3 or vice versa, were excluded
d Subjects with abdominal obesity in round 2, but not round 3 or vice versa, were excluded
e Only subjects with either both abdominal obesity and low HDL-cholesterol levels in round 2 and 3 or with both no abdominal obesity and high HDL-
cholesterol levels were included. Subjects without abdominal obesity and with high HDL-cholesterol levels in round 2 and 3 were used as the reference category
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other positive health outcomes such as, increased HDL
and LDL particle size [15], decreased coronary heart dis-
ease risk [22], and increased longevity [15], all of which
are related to the MetS. In summary, cumulative evi-
dence indicates that Ile405Val is involved in several
metabolic processes, including lipid level control and
weight regulation.
The Cys112Arg genotype of the APOE gene is a non-
synonymous genotype. Together with Arg158Cys
(rs7412), the Cys112Arg forms the ε2ε3ε4 haplotype.
The ε2, ε3 and ε4 ApoE isoforms differ markedly on the
structural and functional level [16]. In our study the Arg
allele of the Cys112Arg genotype was associated with an
increased prevalence of low HDL-cholesterol levels and
an increased prevalence of abdominal obesity. Again the
stratified and adjusted analyses suggested that the asso-
ciations with the prevalence of abdominal obesity and
prevalence of low HDL-cholesterol levels were partly
independent of each other. The ε4 isoform showed a
similar, though less pronounced, pattern of associations.
No associations were observed with Arg158Cys or ε2
isoform, of the ε2ε3ε4 haplotype.
Previous studies generally focused on the ε2, ε3 and ε4
haplotype and did not take associations with the indivi-
dual Arg158Cys and Cys112Arg into account. In line
with our study, the ε4 isoform was associated with a
more detrimental metabolic profile in most studies. A
meta-analysis of 19 studies in 9751 subjects, showed
that ε3/ε4 carriers had lower HDL-cholesterol levels
than ε3/ε3 carriers [23]. Most studies showed either a
positive [24-27] or no [28-31] association between the
ε4 isoform and body weight. However, some showed a
negative association [30,31]. Arbones Mainar et al. [28]
showed that compared to ApoE3 mice, ApoE4 mice fed
a western diet were more prone to the development of
several MetS features, such as increased insulin resis-
tance, decreased fat tolerance and increased fat cell size.
However, they gained less body weight. This suggests
that the positive association between the ε4 isoform and
abdominal obesity may be driven by the development of
other MetS features, such as insulin resistance [28].
Furthermore, these results suggest that the ε4 isoform
may be associated with MetS. This has indeed been
shown in other epidemiological studies [25,26,29].
Strength of our pathway driven candidate gene study
was the relatively large sample size. Contrast and precision
were increased by exclusively including people with con-
sistent MetS phenotype, i.e. classified as healthy or not
healthy for a particular metabolic phenotype over two
measurement rounds. Furthermore we tried to keep the
probability of chance findings low by including only those
SNPS that were related to two or more MetS features with
P < 0.01 into the second round of data-analysis. We found
2 SNPs, which differed significantly from the expected
0.12 SNPs (p < 0.005 chi-square with Yates correction).
However, the 0.12 expected SNPs were obtained assuming
independent random outcomes. As HDL-cholesterol and
abdominal obesity are not completely independent, this
assumption is partly violated. However, the associations
with abdominal obesity and HDL-cholesterol remained
significant in our stratified and adjusted analyses. A weak-
ness of our study may be that blood samples were taken
from non-fasting subjects. This may have randomly
affected the glucose measurements. Another weakness is
that triglycerides levels were not measured in our study.
Therefore, we may have missed SNPs which were related
to hypertriglyceridemia and one or two other MetS fea-
ture. For example, the CETP Ile405Val mutation has been
associated with triglycerides in previous studies [19]. We
therefore expect that in our study population this SNP will
not only be associated with HDL-cholesterol and abdom-
inal obesity, but also with triglyceride levels.
In this explorative study of 373 SNPs among 3575 sub-
jects, we emphasized on the intricate links between sev-
eral MetS features. We have showed that two SNPs,
mainly known for their role in lipid metabolism, influ-
enced both abdominal obesity and low HDL-cholesterol
levels, partly independent of each phenotype. If the pleio-
tropic effects of these genes are further confirmed by
others it might be possible to develop medication which
increases HDL-cholesterol leves and reduces waist cir-
cumference, and so affects the development of MetS
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